KEYMAKER-U04 Substudy 04D: A clinical study of new treatments given with enfortumab vedotin and pembrolizumab in people with urothelial cancer (MK-3475-04D/KEYMAKER-U04)

Trial Identifier: 3475-04D
Sponsor: MSD
Start Date: January 2026
Primary Completion Date: October 2030
Study Completion Date: October 2030
Condition: Bladder Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Petah Tikva, N/A, Israel, 4941492